627 related articles for article (PubMed ID: 26843468)
21. [Diagnosis and management of von Willebrand disease].
Higasa S; Tokugawa T; Sawada A
Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and management of adult patients with von Willebrand disease in South Australia.
Rodgers SE; Lloyd JV; Mangos HM; Duncan EM; McRae SJ
Semin Thromb Hemost; 2011 Jul; 37(5):535-41. PubMed ID: 22102197
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.
Lubetsky A; Martinowitz U; Luboshitz J; Kenet G; Keller N; Tamarin I; Inbal A
Haemophilia; 2002 Sep; 8(5):622-8. PubMed ID: 12199669
[TBL] [Abstract][Full Text] [Related]
25. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
Atiq F; Meijer K; Eikenboom J; Fijnvandraat K; Mauser-Bunschoten EP; van Galen KPM; Nijziel MR; Ypma PF; de Meris J; Laros-van Gorkom BAP; van der Bom JG; de Maat MP; Cnossen MH; Leebeek FWG;
Br J Haematol; 2018 Jul; 182(1):93-105. PubMed ID: 29767844
[TBL] [Abstract][Full Text] [Related]
26. Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: A two decade study.
Abou-Ismail MY; Ogunbayo GO; Secic M; Kouides PA
Am J Hematol; 2018 Feb; 93(2):232-237. PubMed ID: 29098718
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
29. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
30. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
[TBL] [Abstract][Full Text] [Related]
31. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
[TBL] [Abstract][Full Text] [Related]
32. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
Windyga J; von Depka-Prondzinski M;
Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
[TBL] [Abstract][Full Text] [Related]
34. Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease.
De Wee EM; Klaij K; Eikenboom HC; Van Der Bom JG; Fijnvandraat K; Laros-Van Gorkom BA; Mauser-Bunschoten EP; Meijer K; Goverde G; Van Der Linden PW; Rijken DC; Leebeek FW;
Haemophilia; 2012 May; 18(3):444-51. PubMed ID: 21910790
[TBL] [Abstract][Full Text] [Related]
35. von Willebrand disease and aging: an evolving phenotype.
Sanders YV; Giezenaar MA; Laros-van Gorkom BA; Meijer K; van der Bom JG; Cnossen MH; Nijziel MR; Ypma PF; Fijnvandraat K; Eikenboom J; Mauser-Bunschoten EP; Leebeek FW;
J Thromb Haemost; 2014 Jul; 12(7):1066-75. PubMed ID: 24750783
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
[TBL] [Abstract][Full Text] [Related]
38. The genetic basis of von Willebrand disease.
Goodeve AC
Blood Rev; 2010 May; 24(3):123-34. PubMed ID: 20409624
[TBL] [Abstract][Full Text] [Related]
39. Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow-chamber system.
Nogami K; Ogiwara K; Yada K; Shida Y; Takeyama M; Yaoi H; Minami H; Furukawa S; Hosokawa K; Shima M
J Thromb Haemost; 2016 Apr; 14(4):667-74. PubMed ID: 27061057
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
